Nathan P. Lawrence
Geen lopende functies
Vermogen: 44 $ op 30-04-2024
Loopbaan van Nathan P. Lawrence
Eerdere bekende functies van Nathan P. Lawrence
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Boston Biomedical, Inc.
 Boston Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Chemical Co., Ltd., Boston Biomedical, Inc. is a developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The company is based in Norwood, MA. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. The company was founded by Chiang J. Li. Boston Biomedical was acquired by Sumitomo Pharma Co., Ltd. on April 25, 2012 for $2,630 million. | Hoofd Techniek/Wetenschap/O&O | - | - |
| PRESSURE BIOSCIENCES, INC. | Verkoop & Marketing | 01-08-2005 | - |
Opleiding van Nathan P. Lawrence
| University of Miami | Undergraduate Degree |
| Southern Connecticut State University | Graduate Degree |
| Yale University | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 6 |
Operationeel
| Sales & Marketing | 1 |
| Undergraduate Degree | 1 |
| Graduate Degree | 1 |
Sectoraal
| Consumer Services | 4 |
| Health Technology | 2 |
| Commercial Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| PRESSURE BIOSCIENCES, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Boston Biomedical, Inc.
Boston Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Chemical Co., Ltd., Boston Biomedical, Inc. is a developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The company is based in Norwood, MA. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. The company was founded by Chiang J. Li. Boston Biomedical was acquired by Sumitomo Pharma Co., Ltd. on April 25, 2012 for $2,630 million. | Commercial Services |
- Beurs
- Insiders
- Nathan P. Lawrence
- Ervaring